Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 4, 2026, 5:09 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 69 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Hypertension, Grade 1 Clear all
Completed Phase 4 Interventional Results available

Genomic Outcomes of Metformin

NCT02986659
View directory record Official record
Conditions
Coronary Artery Disease, Mild Cognitive Impairment, Obesity, Abdominal, Hypertension
Interventions
Metformin, Placebo
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
65 Years to 79 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 18, 2023 · Synced Oct 4, 2026, 5:09 AM EDT
Not yet recruiting Phase 4 Interventional

Optimizing Preeclampsia Postpartum With Point-of-care Ultrasound

NCT07167862
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Postpartum, Preeclampsia Severe or Mild
Interventions
Butterfly iQ3 ultrasound system for determination of postpartum volume status, Oral furosemide, Intravenous furosemide
Diagnostic Test · Drug
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years and older · Female only
Enrollment
96 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2026 · Synced Oct 4, 2026, 5:09 AM EDT
Completed No phase listed Observational

Preeclampsia Risk Assessment: Evaluation of Cut-offs to Improve Stratification

NCT03815110
View directory record Official record
Conditions
Preeclampsia and Eclampsia, Preeclampsia Severe, Gestational Hypertension, Chronic Hypertension in Obstetric Context, Superimposed Pre-Eclampsia, Preeclampsia Mild
Interventions
Not listed
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years and older · Female only
Enrollment
1,050 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
18
States / cities
Los Angeles, California • San Diego, California • San Francisco, California + 13 more
Source: ClinicalTrials.gov public record
Updated Nov 28, 2022 · Synced Oct 4, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

bpMedManage: Digital Technology to Support Adherence to Hypertension Medications

NCT06307574
View directory record Official record
Conditions
Aging, Mild Cognitive Impairment, Hypertension
Interventions
bpMedManage
Behavioral
Lead sponsor
University of Arizona
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
2
States / cities
Tucson, Arizona • Champaign, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 15, 2025 · Synced Oct 4, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Glaucoma Laser Assessment of Stability and Sustainability

NCT06963684
View directory record Official record
Conditions
Glaucoma
Interventions
Dual-Treatment Direct Selective Laser Trabeculoplasty (DSLT)
Device
Lead sponsor
Twin Cities Eye Consultants
Other
Eligibility
40 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Coon Rapids, Minnesota
Source: ClinicalTrials.gov public record
Updated May 14, 2025 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

visuALL Field Analyzer (vFA) Compared to Standard Humphrey Automated Perimetry

NCT03804684
View directory record Official record
Conditions
Glaucoma, Open-Angle
Interventions
Standard Automatic Perimetry Humphrey Field Analyzer, visuALL Field Analyzer
Diagnostic Test
Lead sponsor
Wills Eye
Other
Eligibility
21 Years to 80 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 29, 2022 · Synced Oct 4, 2026, 5:09 AM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Arlington Longitudinal Optimal Healthy Aging Study (ALOHA)

NCT07180147
View directory record Official record
Conditions
Alzheimer Disease (AD), Cardio Vascular Disease, Mild Cognitive Impairment (MCI), Frailty Syndrome, Disability Physical, Hypertension, Metabolic Syndrome (MetS), Healthy Aging, Obesity &Amp; Overweight
Interventions
Not listed
Lead sponsor
Marymount University
Other
Eligibility
50 Years and older
Enrollment
500 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2031
U.S. locations
1
States / cities
Arlington, Virginia
Source: ClinicalTrials.gov public record
Updated Mar 9, 2026 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

An 8-week Study to Evaluate the Dose Response of AHU377 in Combination With Valsartan 320 mg in Patients With Mild-to-moderate Systolic Hypertension

NCT01281306
View directory record Official record
Conditions
Systolic Hypertension
Interventions
LCZ696, Valsartan, AHU377, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
910 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
19
States / cities
Clearwater, Florida • Chicago, Illinois • Metairie, Louisiana + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 29, 2016 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

A Study of the Efficacy and Safety of Nebivolol Added to Existing Antihypertensive Treatment in Patients With Hypertension

NCT00200434
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 4, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Effect of Electro-Acupuncture on Blood Pressure

NCT00932139
View directory record Official record
Conditions
Hypertension
Interventions
Electro-acupuncture control, Electro-acupuncture test
Procedure
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 85 Years
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2027
U.S. locations
2
States / cities
Irvine, California • Orange, California
Source: ClinicalTrials.gov public record
Updated Apr 15, 2025 · Synced Oct 4, 2026, 5:09 AM EDT
Completed No phase listed Observational

Comparison of Two OCT Device RNFL and GCIPL Measurements in Mild, Moderate, and Severe Glaucoma

NCT07350304
View directory record Official record
Conditions
Glaucoma
Interventions
Optical Coherence Tomography
Diagnostic Test
Lead sponsor
Twin Cities Eye Consultants
Other
Eligibility
18 Years and older
Enrollment
141 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Coon Rapids, Minnesota
Source: ClinicalTrials.gov public record
Updated Jan 20, 2026 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Evaluation of Soluble Epoxide Hydrolase (s-EH) Inhibitor in Patients With Mild to Moderate Hypertension and Impaired Glucose Tolerance

NCT00847899
View directory record Official record
Conditions
Hypertension, Impaired Glucose Tolerance
Interventions
AR9281, Placebo
Drug
Lead sponsor
Arete Therapeutics
Industry
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
30
States / cities
Mobile, Alabama • Muscle Shoals, Alabama • Anaheim, California + 26 more
Source: ClinicalTrials.gov public record
Updated Nov 20, 2009 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Effect and Safety of Marealis RPC (Refined Peptide Concentrate) in Mild or Moderate Hypertensive Subjects

NCT01974570
View directory record Official record
Conditions
Prehypertension
Interventions
Marealis refined peptide concentrate, Placebo
Dietary Supplement
Lead sponsor
KGK Science Inc.
Industry
Eligibility
30 Years to 75 Years
Enrollment
144 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2015
U.S. locations
1
States / cities
Addison, Illinois
Source: ClinicalTrials.gov public record
Updated Dec 24, 2015 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy of Nebivolol in Hypertensive Patients

NCT00200473
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
800 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 20, 2005 · Synced Oct 4, 2026, 5:09 AM EDT
Recruiting Not applicable Interventional

Glaukos® iStent Infinite Trabecular Micro-Bypass System in Subjects With Mild to Moderate Primary Open-angle Glaucoma

NCT06057051
View directory record Official record
Conditions
Glaucoma
Interventions
iStent Infinite
Device
Lead sponsor
Glaukos Corporation
Industry
Eligibility
35 Years and older
Enrollment
245 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2027
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated Sep 28, 2023 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Not applicable Interventional

A Comparison of Two Ab Interno Procedures in the Treatment of Glaucoma in Patients Undergoing Cataract Extraction

NCT02784249
View directory record Official record
Conditions
Open Angle Glaucoma
Interventions
Goniotomy, Trabecular Micro-Bypass Stent, Cataract Extraction
Procedure · Device
Lead sponsor
New World Medical, Inc.
Industry
Eligibility
18 Years to 90 Years
Enrollment
166 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
La Crosse, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 14, 2021 · Synced Oct 4, 2026, 5:09 AM EDT
Terminated Phase 2 Interventional

LFF269 Compared to Placebo After Treatment in Subjects With Essential Hypertension

NCT01373086
View directory record Official record
Conditions
Hypertension
Interventions
LFF269, Eplerenone, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years to 75 Years
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011
U.S. locations
11
States / cities
Anaheim, California • Fort Myers, Florida • Miramar, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Dec 17, 2020 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

A Pilot Study Comparing Nebivolol and Atenolol and Its Effects With Exercise in Patients With Mild to Moderate Hypertension

NCT00200421
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol and Atenolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2005 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

Dosing Study of the Effects of Nebivolol on Blood Pressure in Black Patients With Mild to Moderate Hypertension

NCT00145236
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Sep 14, 2005 · Synced Oct 4, 2026, 5:09 AM EDT
Active, not recruiting Not applicable Interventional

Preeclampsia Educational Program Study (PrEPS)

NCT06373367
View directory record Official record
Conditions
Preeclampsia, Preeclampsia Severe, Preeclampsia Mild, Preeclampsia Postpartum
Interventions
Illustration based application, Text based application
Other
Lead sponsor
MemorialCare Health System
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2025 · Synced Oct 4, 2026, 5:09 AM EDT
Terminated Phase 3 Interventional Results available

Study to Evaluate Symptoms in Patients Treated With Nebivolol or Metoprolol Extended-release (ER) for Hypertension

NCT00547300
View directory record Official record
Conditions
Hypertension
Interventions
Metoprolol ER, Nebivolol
Drug
Lead sponsor
Forest Laboratories
Industry
Eligibility
18 Years to 80 Years
Enrollment
49 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
24
States / cities
Birmingham, Alabama • Beverly Hills, California • Encinitas, California + 21 more
Source: ClinicalTrials.gov public record
Updated May 21, 2019 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2 Interventional Results available

CAndesartan vs LIsinopril Effects on the BRain

NCT01984164
View directory record Official record
Conditions
Hypertension, Mild Cognitive Impairment
Interventions
Candesartan, Lisinopril
Drug
Lead sponsor
Emory University
Other
Eligibility
55 Years and older
Enrollment
176 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Feb 21, 2021 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 3 Interventional

A Study of the Safety and Efficacy of Long-Term Nebivolol Use in Hypertensive Patients

NCT00200499
View directory record Official record
Conditions
Hypertension
Interventions
Nebivolol
Drug
Lead sponsor
Mylan Bertek Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
845 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2003
U.S. locations
1
States / cities
Morgantown, West Virginia
Source: ClinicalTrials.gov public record
Updated Dec 16, 2005 · Synced Oct 4, 2026, 5:09 AM EDT
Completed Phase 2 Interventional

Study of Nifedipine GITS and Candesartan Combination Compared to Monotherapy in Patients With Essential Hypertension

NCT01303783
View directory record Official record
Conditions
Hypertension, Essential
Interventions
Candesartan cilexetil (Atacand), 4 mg, Candesartan cilexetil (Atacand), 8 mg, Nifedipine GITS (Adalat, BAYA1040), 20 mg, Nifedipine GITS (Adalat, BAYA1040), 30 mg, Nifedipine GITS (Adalat, BAYA1040), 60 mg, Placebo, Candesartan cilexetil (Atacand), 16 mg, Candesartan cilexetil (Atacand), 32 mg
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
1,381 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
23
States / cities
Mobile, Alabama • Los Angeles, California • Coral Gables, Florida + 18 more
Source: ClinicalTrials.gov public record
Updated Apr 18, 2017 · Synced Oct 4, 2026, 5:09 AM EDT